ERCC1表达水平与晚期非小细胞肺癌患者化疗疗效的相关性

目的:研究Ⅲb、Ⅳ期非小细胞肺癌(NSCLC)患者肿瘤组织内核苷酸切除修复交叉互补组1(excision repair cross complementation group1,ERCC1)基因mRNA表达水平与含铂类方案化疗疗效的相关性。方法:符合入选条件的患者56例,均为Ⅲb、Ⅳ期患者。所有的患者经皮肺穿刺或经纤支镜活检病理证实为NSCLC。化疗前利用RNA提取技术及RealtimeRT-PCR技术对其组织学标本进行ERCC1 mRNA相对定量分析。患者分别给予4～6个周期的含铂类方案化疗(吉西他滨/顺铂、紫杉醇/顺铂方案),对患者化疗后的总生存期(overall survival,OS)、肿瘤进展时间(time to progression,TTP)及化疗后反应率(response rate,RR)进行评估。结果:56例患者活检标本的ERCC1 mRNA相对于内控管家基因GAPDH mRNA表达的平均表达水平为6.1×103。以ERCC1 mRNA表达水平≥6.1×103的22例患者作为高表达组,以ERCC1 mRNA表达水平<6.1×103的34例患者作为低表达组。高表达组患者化疗后RR、OS及TTP...

Relationship between the expression of ERCC1 and the curative effect of chemotherapy in the patients with nonsmall-cell lung cancer in late stage

Objective To study the relationship between the mRNA expression of excision repair cross complementation group 1(ERCC1) and the curative effect of cisplatin-based chemotherapy in the patients with stage Ⅲb/Ⅳ nonsmall-cell lung cancer (NSCLC). Methods 56 patients were diagnosed by pathologic examination of percutaneous needle aspiration or fiberobronchoscopy biopsy. The relative quantitive analysis of ERCC1 mRNA in the histological specimen was performed by the extractive technique of RNA and real time RT-PC...